Skip to main content
. 2024 Mar 28;12(4):750. doi: 10.3390/biomedicines12040750

Table 2.

Descriptive statistics of laboratory values tested in patients with IgA vasculitis and control group.

Parameter Patients with IgA Vasculitis (Median, Interquartile Range) Control Group (Median, Interquartile Range) (N = 33) p * p ** p *** p **** p ***** p ******
Onset (N = 69) Follow Up 3 Months (N = 63) Follow Up 6 Months (N = 56)
S100A8/A9 (ng/mL) 5348.00 (3171.00–8000.00) 2115.00 (1338.00–2725.00) 2013.00 (1196.40–4126.15) 1132.00 (797.50–2085.30) <0.0001 0.0086 0.0011 <0.0001 <0.0001 0.3364
ESR (mm/h) 15.00 (9.00–23.00) 6.00 (4.00–9.00) 7.00 (5.00–10.75) 5.00 (4.00–9.25) <0.0001 0.3540 0.0958 <0.0001 <0.0001 0.3866
CRP (mg/L) 5.50 (2.52–16.28) 0.70 (0.30–1.78) 0.90 (0.30–1.48) 0.00 (0.00–0.00) <0.0001 0.1474 0.1010 <0.0001 <0.0001 0.5718
WBC (×109/L) 10.10 (8.28–12.10) 7.30 (5.96–9.00) 6.95 (5.75–8.02) 5.50 (4.70–6.60) <0.0001 0.0028 0.0045 <0.0001 <0.0001 0.1173
C3 (g/L) 1.35 (1.20–1.52) 1.16 (1.06–1.31) 1.19 (1.06–1.29) 1.05 (0.94–1.20) 0.0062 0.1288 0.1784 0.0091 0.0058 0.7504
C4 (g/L) 0.26 (0.20–0.33) 0.21 (0.16–0.25) 0.22 (0.16–0.26) 0.16 (0.13–0.24) 0.0102 0.1491 0.1532 0.0072 0.0126 0.9835
Fibrinogen (g/L) 3.40 (2.70–3.80) 2.60 (2.40–3.30) 2.70 (2.30–3.05) 2.55 (2.23–2.85) 0.0181 0.3822 0.7725 0.0010 <0.0001 0.2705
Albumin (g/L) 38.70 (35.63–41.92) 43.85 (40.65–45.48) 44.20 (42.00–46.70) 44.61 (40.65–47.10) 0.0094 0.4796 0.6462 <0.0001 <0.0001 0.0479
Gamma globulin (g/L) 9.60 (7.75–11.60) 9.03 (7.32–10.72 9.30 (7.50–10.90) 9.72 (8.24–12.02) 0.8685 0.6838 0.3377 0.5991 0.2053 0.4876
Ferritin (ng/mL) 64.00 (45.50–94.95) 22.80 (13.20–40.00) 28.00 (16.35–42.85) 31.50 (21.00–48.00) 0.0448 0.2951 0.0893 <0.0001 <0.0001 0.6486

Abbreviations: ESR—erythrocyte sedimentation rate; CRP—C-reactive protein; WBC—white blood cells. Legend: p *—comparison between values in patients at onset of disease and patients in control group; p **—comparison between values in patients three months after onset of disease and patients in control group; p ***—comparison between values in patients six months after onset of disease and patients in control group; p ****—comparison between values in patients at onset of disease and patients three months after onset of disease; p *****—comparison between values in patients at onset of disease and patients six months after onset of disease; p ******—comparison between values in patients three months after onset of disease and patients six months after onset of disease. Statistically significant values (p < 0.05) are bolded in table.